Ranbaxy Set To launch Aricept Generic In U.S. As FDA OKs Ohm Labs Data; Will Lipitor Be Next ?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's largest drug maker Ranbaxy - now part of Japanese pharma Daiichi Sankyo - is set to launch a generic version of the blockbuster Alzheimer's disease drug Aricept (donepezil) in the U.S. market, leading experts to predict that Ranbaxy may also be on track to launch a generic of the world's best selling drug, Lipitor (atorvastatin)
You may also be interested in...
The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics
Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.
The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics
Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.
As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?
MUMBAI - As Ranbaxy struggles to deal with U.S. FDA allegations of GMP violations and data falsification at its two Indian manufacturing sites - Paonta Sahib and Dewas - clouds are gathering over its ability to launch a generic equivalent of the planet's largest drug brand Lipitor (atorvastatin) in the United States, about a year from now